

ASX ANNOUNCEMENT

DRP ALLOCATION PRICE

22 SEPTEMBER 2023

Melbourne, Australia – Vitura Health Limited (ASX: VIT) (**Vitura and Company**) advises that the allocation price for the shares to be issued under the Company's Dividend Reinvestment Plan (**Plan**) in respect of its 2023 dividend is \$0.3078 (**Allocation Price**).

The Allocation Price has been determined in accordance with the Plan rules and was calculated by applying a 3% discount to the daily volume weighted average price of the Company's shares on each of the ten consecutive trading days during the period from 8 September 2023 to 21 September 2023 (inclusive of those dates).

Of the total dividend payable of \$5,580,321, based on the payment rate of \$0.01 per share, a total of \$142,000 (being 2.54% of the total dividend payable) will be attributable to the 461,294 shares expected to be issued to participants in the Plan on the dividend payment date of 28 September 2023.

Pursuant to the Listing Rules, the Company will today release an updated ASX Appendix 3A.1.

** ENDS **



About Vitura Health Limited (ASX:VIT)

Vitura Health Limited is listed on the ASX (ASX:VIT) and, via its wholly owned subsidiaries, operates the following businesses:

- Burleigh Heads Cannabis - operates the market leading prescriber, patient, pharmacy and supplier online platform, CanView, which sells and distributes 260+ product SKUs within Australia from 39 international and domestic medicinal cannabis brands.
 - CanView is being developed to be a complete end-to-end healthcare ecosystem designed to provide doctors, pharmacists and patients with a simple and cost-effective way to facilitate the treatment of patients with increased efficiency and compliance. The CanView system is based on a medicines wholesaling platform which seamlessly brings together a number of disparate SAAS (software-as-a-service) providers including inventory control, invoicing, customer management, reporting and analytics, all linked together through customised integration from third party providers. Underpinning the suite of SAAS elements are a number of bespoke, internally-generated operating procedures and intellectual property assets, supported by the CanView customer support and infield customer engagement teams. Through the integration of the different elements which together make up CanView, the platform provides the best user experience in the industry.

Through the Company's relationships with third party integrators, CanView provides Australian doctors with the ability to integrate their patient management systems directly with the platform and to use their patient information to generate electronic prescriptions within the CanView platform, without the need to input the patient's details. Prescriptions are then sent directly to the CanView patient app where patients can manage their treatment and submit the prescription and subsequent repeats to one of the 3,600+ Australian pharmacies with accounts on CanView for dispensing.

While the Company's current operations focus on the sale and distribution of medicinal cannabis products, Vitura is fully licensed and equipped, via its two state-of-the-art distribution centres in Melbourne and the Gold Coast, to distribute all products under Schedules 2, 3, 4, 8 and 9. The establishment during the year of the Company's joint venture to distribute psychedelic products, including MDMA and Psilocybin, is a timely example of the many opportunities that the Company believes can be seamlessly integrated into its existing digital health platform business.

- The Company owns 50% of Cortexa Pty Ltd, an incorporated joint venture with Canadian-based PharmAla Biotech (CSE:MDMA). Cortexa aims to be the leading supplier of psychedelics, GMP MDMA and GMP psilocybin, for research and therapeutic use in Australia.
- The Company owns CDA Clinics that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.
- The Company owns 75.5% of Cannadoc Health Pty Ltd, a medicinal cannabis clinic business that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.

www.vitura.com.au

www.canview.com.au

www.burleighheadscannabis.com

www.cortexa.com.au

www.cdaclinics.com.au

www.cannadoc.com.au

**Authorised by**

Rodney Cocks, Chief Executive Officer and Executive Director

Contact

Vitura Health Limited

Rodney Cocks

Chief Executive Officer and Executive Director

1300 799 491

info@vitura.com.au

Media enquiries

Tim Fogarty

The Civic Partnership

+61 400 179 075

tim.fogarty@civicpartners.com.au

Forward-looking statements

This announcement includes forward-looking statements which may be identified by words such as 'anticipates', 'believes', 'expects', 'intends', 'may', 'will', 'could', or 'should' and other similar words that involve risks and uncertainties. These forward-looking statements are based on the Company's expectations and beliefs concerning future events as at the date of this announcement. Forward-looking statements are necessarily subject to risks, uncertainties and other factors, many of which are outside the control of the Company, which could cause actual results to differ materially from such statements. The Company makes no undertaking to update or revise the forward-looking statements made in this announcement to reflect any change in circumstances or events after the date of this announcement.